Product details

By continuing to use our site you consent to the use of cookies as described in our privacy policy unless you have disabled them.
You can change your cookie settings at any time but parts of our site will not function correctly without them.

Abstract

Formed on 6 April 1999 through the merger of Zeneca Group Plc from the UK, and Astra AB from Sweden, AstraZeneca is engaged in research, development, manufacturing and marketing of prescription pharmaceuticals and health care services. By 2005, it was among the top five pharmaceutical companies in the world with a turnover of US$21.4 billion. This case, while highlighting the rationale behind the formation of AstraZeneca, offers scope to discuss its growth strategy of focusing on the research and development of innovative drugs to fulfill global health care needs.
Location:
Other setting(s):
September 2005

About

Abstract

Formed on 6 April 1999 through the merger of Zeneca Group Plc from the UK, and Astra AB from Sweden, AstraZeneca is engaged in research, development, manufacturing and marketing of prescription pharmaceuticals and health care services. By 2005, it was among the top five pharmaceutical companies in the world with a turnover of US$21.4 billion. This case, while highlighting the rationale behind the formation of AstraZeneca, offers scope to discuss its growth strategy of focusing on the research and development of innovative drugs to fulfill global health care needs.

Settings

Location:
Other setting(s):
September 2005

Related